MRM
MEDIROM Healthcare Technologies
About: MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
Employees: 1,051
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.73% more ownership
Funds ownership: 1.55% [Q4 2024] → 2.28% (+0.73%) [Q1 2025]
40% less funds holding
Funds holding: 5 [Q4 2024] → 3 (-2) [Q1 2025]
48% less capital invested
Capital invested by funds: $127K [Q4 2024] → $66K (-$60.8K) [Q1 2025]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for MRM.
Financial journalist opinion
Based on 4 articles about MRM published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements
MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements. The Company's ADSs had been $1.00 per share or greater.
Neutral
GlobeNewsWire
2 weeks ago
Specific Health Guidance Service Utilizing the "Lav" Healthcare App: Surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals!
TOKYO, May 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) ("MEDIROM," "we,” “us” or “our”), a holistic healthcare company based in Japan, announces that its subsidiary, MEDIROM MOTHER Labs, Inc., has surpassed 100 cumulative contracted companies and 10,000 cumulative supported individuals in its specific health guidance service utilizing the healthcare app "Lav."
Neutral
GlobeNewsWire
3 weeks ago
MEDIROM Healthcare Technologies Inc. Announces 22% Rise in Revenue and 20% Improvement in Earnings for 2024; Webcast to Discuss Financial Results to be held on May 21st, 2025 at 8:30 AM ET
TOKYO, May 20, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that for the year ended December 31, 2024, the Company had total revenue of $52,736,000, a 22% increase over total revenue of $43,388,000 for the year ended December 31, 2023. (The Company reports its financial results in Japanese yen and figures presented in this press release in US dollars have been translated for convenience at the exchange rate of ¥ 157.37 = US$1.00. See “Convenience Translations to US Dollars” below for more information.)
Neutral
GlobeNewsWire
3 weeks ago
MEDIROM Healthcare Technologies Inc. to Host Webcast on May 21, 2025 at 8:30 AM ET to Discuss 2024 Financial Results
TOKYO, May 19, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”) today announced that it will host a webcast to review the Company's financial results for the fiscal year ended December 31, 2024, on Wednesday, May 21, 2025 at 8:30 am Eastern Time.
Neutral
GlobeNewsWire
2 months ago
MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing
TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that it has obtained a new unsecured short-term bank loan in the amount of JPY350 million (approximately $2.4 million*). The Company has used JPY200 million of the loan funds for repayment of indebtedness of MEDIROM Mother Labs Inc., a subsidiary of the Company which is also a guarantor of the new loan, and the Company intends to use the remainder of the loan funds for general working capital, including Mother Bracelet development. The loan bears interest at a rate of 1.875% per year.
Neutral
GlobeNewsWire
3 months ago
MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)
TOKYO, March 13, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs Inc. (“Mother Labs”), a subsidiary of the Company, has made a second investment in Mother Labs' Series A financing at a pre-money valuation of JPY9 billion (as of March 13, 2025, approximately US$60 million). This new investment follows Mr. Hayami's initial investment in the Series A financing in December 2024. Mr. Hayami is a committed senior executive of Mother Labs and shares MEDIROM's corporate philosophy and vision as well as commitment to future growth potential.
Neutral
GlobeNewsWire
4 months ago
MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs)
Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6% Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6%
Neutral
GlobeNewsWire
4 months ago
MEDIROM MOTHER Labs Provides MOTHER Bracelet®︎ Device and Remote Health Monitoring System, REMONY, to TOPPAN Inc.
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare technologies Inc. (NASDAQ: MRM) (“MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, is pleased to announce that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”) is now providing its remote health monitoring system, REMONY, and charging-free smart tracker device, MOTHER Bracelet®︎, to the Electronics Division of TOPPAN Inc. (Tokyo Stock Exchange: 7911).
Neutral
GlobeNewsWire
5 months ago
MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs)
Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5% Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5%
Neutral
GlobeNewsWire
6 months ago
MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round
TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. “We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM's current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji.
Charts implemented using Lightweight Charts™